Court permits generic version of Copaxone a year sooner
Posted: Mon Jul 29, 2013 12:53 am
Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court Friday.
The U.S. Court of Appeals for the Federal Circuit issued its decision in a patent fight between Teva and rivals Sandoz and Mylan Inc.... Read More - http://www.ms-uk.org/index.cfm/copaxone
The U.S. Court of Appeals for the Federal Circuit issued its decision in a patent fight between Teva and rivals Sandoz and Mylan Inc.... Read More - http://www.ms-uk.org/index.cfm/copaxone